Table 2.
Clinical Remission and Clinical Response Following Treatment Switch
| Study | Treatment Switch | Patients with UC, n (%) | Patients Who Switched Treatment, n (%) | Time of Assessment | Switched Patients Achieving Clinical Remission, n (%) | Switched Patients Achieving Clinical Response, n (%) |
|---|---|---|---|---|---|---|
| Studies reporting on switching within treatment classa | ||||||
| Baert et al (2014)25 | IFX>ADA | 73 (100) | 73 (100) | 12 weeks | — | 55 (75.3) |
| Baert et al (2014)25 | IFX>ADA | 73 (100) | 73 (100) | 12 months (52 weeks) | — | 38 (52.1) |
| Baki et al (2015)26 | IFX>ADAADA>IFX | 72 (100) | 72 (100) | — | 2 (2.8) | — |
| Christensen et al (2015)33 | IFX>ADA | 33 (100) | 33 (100) | 12 weeks | 6 (18.2) | 15 (45.5) |
| Christensen et al (2015)33 | IFX>ADA | 33 (100) | 33 (100) | 12 months (52 weeks) | 6 (18.2) | 8 (24.2) |
| Peyrin-Biroulet et al (2007)56 | IFX>ADA | 10 (100) | 10 (100) | — | 1 (10) | 3 (30) |
| Taxonera et al (2011)64 | IFX>ADA | 30 (100) | 30 (100) | 4 weeks | 3 (10) | 16 (53.3) |
| Taxonera et al (2011)64 | IFX>ADA | 30 (100) | 30 (100) | 12 weeks | 8 (26.7) | 18 (60) |
| Taxonera et al (2017)68 | IFX/ADA>GOL | 142 (100) | 85 (59.9) | 8 weeks | 45 (52.9) | 92 (64.7) |
| Taxonera et al (2017)68 | IFX/ADA>GOL | 142 (100) | 85 (59.9) | 12 months | 50 (58.8) | — |
| Tursi et al (2014)71 | IFX>ADA | 15 (100) | 15 (100) | 24 weeks | 11 (73.3) | — |
| Tursi et al (2014)71 | IFX>ADA | 15 (100) | 15 (100) | 54 weeks | 15 (100) | — |
| Viola et al (2019)73 | ADA/GOL>IFX | 76 (100) | 76 (100) | 3 months | 29 (38.2) | 24 (31.6) |
| Viola et al (2019)73 | ADA/GOL>IFX | 76 (100) | 76 (100) | 6 months | 29 (38.2) | 14 (18.4) |
| Viola et al (2019)73 | ADA/GOL>IFX | 76 (100) | 76 (100) | 12 months | 26 (34.2) | 7 (9.2) |
| Stefanovic et al (2021)63 | GOL>IFX | 30 (100) | 11 (36.7) | 13 months (57 weeks) | 9 (81.8) | — |
| Studies reporting on switching treatment MOAb | ||||||
| Stefanovic et al (2021)63 | GOL>VDZ | 30 (100) | 3 (10) | 13 months (57 weeks) | 3 (100) | — |
| Wang et al (2019)74 | Anti-TNF>VDZ | 5 (12.2) | 5 (100) | 6 months | 5 (100) | — |
| Wang et al (2019)74 | Anti-TNF>VDZ | 5 (12.2) | 5 (100) | 12 months | 5 (100) | — |
Notes: aSwitching between anti-TNF agents. bSwitching between drugs with different mechanisms of action.
Abbreviations: Anti-TNF, tumor necrosis factor inhibitor; ADA, adalimumab; GOL, golimumab; IFX, infliximab; MOA, mechanism of action; UC, ulcerative colitis; VDZ, vedolizumab.